Head of AstraZeneca Jordan speaks on vaccine outreach

Even though many countries have suspended the use of the AstraZeneca vaccine, many resumed it after the EMA stressed the jab’s benefits. (Photo: AFP)
(Photo: Jordan News)
AMMAN — AstraZeneca Jordan on Monday evening underlined its commitment to cooperate with the Jordanian government to curb the impact of the COVID-19 pandemic in an interview with the Jordan News Agency, Petra.اضافة اعلان
Abdulkareem Dissi, the pharmaceutical's regional director said that the company is actively working with international organizations, governments, healthcare leaders, and industry and civil society to end the pandemic, stressing the need to continue cooperation with the Jordanian government to that end.

AstraZeneca’s partnership with the Jordanian government has led to the delivery of more than 600,000 doses of the COVID-19 vaccine to date. "Thousands of lives are being saved every day as a result of such urgent and committed cooperation," Dissi said.

He also lauded the efforts exerted by His Majesty King Abdullah and the government throughout the pandemic to provide the appropriate infrastructure, hospitals, and immunization centers, in addition to launching awareness campaigns on the vaccine.

"Recognizing the urgent need for an effective COVID-19 vaccine to help defeat the virus, we joined forces with the University of Oxford in April 2020 to make a meaningful difference to the course of the pandemic and help save lives,” Dissi said. “This landmark partnership brought together Oxford University’s world-class expertise in vaccinology with AstraZeneca’s global development and manufacturing capabilities. Together we committed to providing the vaccine broadly and equitably around the world, at no profit during the pandemic period."

To help meet global demand for a COVID-19 vaccine, AstraZeneca rapidly conducted due diligence with more than 60 potential partners to ultimately build a global supply network of more than 25 proven manufacturing organizations in 15 countries with the capability and capacity to supply the vaccine, he added.

On vaccine safety, Dissi said: "Ensuring the safety of our vaccine is paramount and we are actively working with the regulators and scientific community to understand extremely rare blood clotting events that have been reported, including information to drive early diagnosis and intervention, and appropriate treatment for the condition."

He added that the company had partnered with different organizations with large-scale manufacturing capabilities to ensure that the vaccine could be manufactured on a larger scale and reach people in need as quickly as possible.

Read more National news